Guangzhou Doublle Biological Products Co., Ltd. was founded by Dr. Wenlin Huang, who is virologist and oncologist. He is currently the rotating chairman of the Asia-Pacific Cell and Gene Therapy Association, an outstanding talent in Guangzhou Development Zone, a professor at Sun Yat-Sen University Cancer Center, and an honorary professor at the Chinese University of Hong Kong. Dr. Huang Wenlin has beenfocusing on the development and transformation of gene engineering technology to clinical applications such as tumor gene therapy, immune cell therapy, and vaccines.

Since its establishment, the company has always focused on technological research and development, and has formed a relatively complete development systemwith a tellented team led by Dr. Huang WenlinThroughout years of effort, the company has created a gene therapeutic  development platform, and developed the cutting-edge core technologies which has enabled the company to continuously develop new biologics. As a supporting unit, two provincial-level enterprise key laboratories (engineering laboratories) for anti-tumor drug R&D and one municipal-level enterprise key laboratory for gene therapy have been established. Further more and five new drug R&D functional platforms have been established under the support of three laboratory platforms, including Gene therapy biologics commercial scale production and quality control platform, cell biotherapy R&D and manufacturing platform, tumor vaccine and specific immunotherapy product platform, construction of anti-tumor lead macromolecule candidates and pharmacodynamics platform, etc.

After decades of continuous innovation and development, our company has formed a sustainable product pipelines. including E10A, E10B, E10C, E10D, E10F, E10G, E10H, E10I, E10J, etc, just to name a few. Among them, E10A (Recombinant Human Endostatin Adenovirus Injection) is the first gene therapy drug to enter clinical phase III trials in China同時、E10H (Autologous Natural Killer Cell Injection) is the first NK cell therapy drug approved for clinical trials in China.